Pharmacy and therapeutics committees: leadership opportunities in medication safety for medical toxicologists.
作者信息
Perrone Jeanmarie, Nelson Lewis S
出版信息
J Med Toxicol. 2011 Jun;7(2):99-102. doi: 10.1007/s13181-011-0147-5.
Abstract
摘要
相似文献
1
Pharmacy and therapeutics committees: leadership opportunities in medication safety for medical toxicologists.
J Med Toxicol. 2011 Jun;7(2):99-102. doi: 10.1007/s13181-011-0147-5.
2
Multifaceted approach to reducing preventable adverse drug events.
Am J Health Syst Pharm. 2003 Mar 15;60(6):582-6. doi: 10.1093/ajhp/60.6.582.
3
[Pharmacy and therapeutics committees in Brazil: lagging behind international standards].
Rev Panam Salud Publica. 2006 Jan;19(1):58-63. doi: 10.1590/s1020-49892006000100014.
4
Literature review on the structure and operation of Pharmacy and Therapeutics Committees.
Int J Clin Pharm. 2011 Jun;33(3):475-83. doi: 10.1007/s11096-011-9501-6. Epub 2011 Mar 18.
5
Managing conflicts of interest in pharmacy and therapeutics committees: A proposal for multicentre formulary development.
J Clin Pharm Ther. 2020 Apr;45(2):249-255. doi: 10.1111/jcpt.13067. Epub 2019 Oct 27.
6
Improving pharmacy and therapeutics committee operations.
Am J Hosp Pharm. 1984 Sep;41(9):1767-77.
7
The JCAHO Agenda for Change: what changes in pharmacy and P & T activities do you need to prepare for in 1994?
Hosp Formul. 1994 Jan;29(1):54-6, 58-60, 64 passim.
8
Quality improvement in the use of medications through a drug use evaluation service.
Top Hosp Pharm Manage. 1992 Oct;12(3):47-56.
9
A survey of Pharmacy and Therapeutic committees across Canada: scope and responsibilities.
Can J Clin Pharmacol. 2009 Winter;16(1):e171-7. Epub 2009 Feb 25.
10
Innovative approach for sustaining an institutional medication safety committee.
Am J Health Syst Pharm. 2020 May 19;77(11):826-829. doi: 10.1093/ajhp/zxaa068.
引用本文的文献
1
Drug and therapeutics committees in Jordanian hospitals: a nation-wide survey of organization, activities, and drug selection procedures.
Pharm Pract (Granada). 2019 Oct-Dec;17(4):1590. doi: 10.18549/PharmPract.2019.4.1590. Epub 2019 Nov 3.
2
The Value of Pediatricians on Pharmacy and Therapeutics Committees.
P T. 2019 Jan;44(1):2-4.
3
A P&T Committee's Transition to a Complete Electronic Meeting System-A Multisite Institution Experience.
P T. 2017 Oct;42(10):641-651.
4
Position statement: medical toxicologist participation in medication management and safety systems.
J Med Toxicol. 2015 Mar;11(1):147-8. doi: 10.1007/s13181-013-0361-4.
本文引用的文献
1
Conflicts of interest on pharmacy and therapeutics committees at academic medical centers.
J Med Toxicol. 2011 Jun;7(2):175-6. doi: 10.1007/s13181-011-0148-4.
2
How many "me-too" drugs is too many?
JAMA. 2011 Feb 16;305(7):711-2. doi: 10.1001/jama.2011.152.
3
Off-label prescribing of drugs for children.
Curr Drug Saf. 2011 Feb 1;6(1):46-8. doi: 10.2174/157488611794479973.
4
The formulary process from a risk management perspective.
Pharmacotherapy. 2010 Jun;30(6 Pt 2):42S-47S. doi: 10.1592/phco.30.pt2.42S.
5
Failure to discount for conflict of interest when evaluating medical literature: a randomised trial of physicians.
J Med Ethics. 2010 May;36(5):265-70. doi: 10.1136/jme.2009.034496.
6
Medication errors recovered by emergency department pharmacists.
Ann Emerg Med. 2010 Jun;55(6):513-21. doi: 10.1016/j.annemergmed.2009.10.012. Epub 2009 Dec 11.
7
Pharmacoeconomics: principles and relevance to the activities of drug and therapeutics committees.
Clin Med (Lond). 2009 Oct;9(5):490-2. doi: 10.7861/clinmedicine.9-5-490.
8
President Obama's health care reform policies: Issues of interest to P&T committees.
P T. 2009 Jun;34(6):296-308.
9
A survey of Pharmacy and Therapeutic committees across Canada: scope and responsibilities.
Can J Clin Pharmacol. 2009 Winter;16(1):e171-7. Epub 2009 Feb 25.
10
Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
Ann N Y Acad Sci. 2008 Oct;1141:284-303. doi: 10.1196/annals.1441.026.
Zotero 插件